Healing the Planet to Heal the Patient: WHO Launches Global Push to Decarbonize the Pharmaceutical Industry

GENEVA — In a major step toward addressing the healthcare sector’s hidden environmental toll, the World Health Organization (WHO) spearheaded a landmark forum on May 8, 2026, to establish a global regulatory roadmap for decarbonizing the pharmaceutical industry. Bringing together more than 100 participants from 30 global institutions—including regulators, health agencies, procurement organizations, and industry executives—the virtual consultation focused on creating “greener” regulatory pathways. The central objective of the initiative is to drastically reduce the carbon footprint of medicine production without compromising patient safety, drug efficacy, or global access to life-saving treatments.

“Climate change and health is a strategic priority for WHO,” stated Dr. Rogério Gaspar, Director of WHO’s Department of Regulation and Prequalification. “The objective of this initiative is to clarify where regulation currently constrains or slows down decarbonization, identify opportunities for regulatory leadership and flexibility, and build consensus across regulators, industry, and global health actors on practical pathways that preserve quality, safety, and access.”

The Pharmaceutical Industry’s Hidden Climate Footprint

While the healthcare sector is dedicated to human healing, its operational infrastructure contributes significantly to environmental degradation. The global healthcare industry is responsible for an estimated 4.4% of total global greenhouse gas emissions annually—a footprint larger than that of the automotive or aviation sectors. Crucially, the Alliance for Transformative Action on Climate and Health (ATACH) notes that roughly 70% to 71% of these emissions originate upstream within the supply chain, specifically during the manufacturing and distribution of pharmaceutical and biotechnology products.

Data indicates that this issue is accelerating. According to a comprehensive longitudinal study by Leiden University published in The Lancet Planetary Health, greenhouse gas emissions related to pharmaceutical consumption surged by 77% over a 24-year period analyzed. This spike was primarily driven by increased healthcare spending and drug utilization globally, particularly in expanding markets like China, while manufacturing efficiency gains largely stalled after 2008.

A primary driver of this carbon intensity is the production of Active Pharmaceutical Ingredients (APIs)—the biologically active components of medications. Synthesizing APIs requires complex chemistry, multi-step molecular reactions, and substantial energy inputs. Consequently, the manufacturing process for a specialized medical molecule can have a global warming potential up to 25 times larger than that of standard chemical manufacturing. In total, API synthesis accounts for roughly one-quarter of all emissions generated by pharmaceutical corporations.

Manufacturing and Procurement: Catalysts for Change

Because manufacturing represents the largest emissions hotspot across the pharmaceutical value chain, regulatory experts view process refinement as an untapped opportunity. Janet Ginnard, Director of Strategy at Unitaid, highlighted that substantial emissions cuts can be achieved through greener manufacturing practices, such as transitioning facilities to renewable energy and utilizing continuous flow chemistry, without driving up manufacturing costs or threatening drug supplies.

“Regulators are a key stakeholder group in helping understand and overcome barriers to decarbonization,” Ginnard emphasized. “There is no shortage of opportunities, but prioritization will be important to identify those actions that can deliver the greatest impact while protecting access to medicines.”

Simultaneously, global health systems are leveraging procurement power to drive market behavior. Agencies like NHS England are increasingly embedding environmental sustainability into their purchasing contracts. By requiring pharmaceutical suppliers to measure, disclose, and systematically reduce their carbon outputs, large-scale health systems are creating strong commercial incentives for eco-friendly manufacturing innovation.

Real-World Success: The Shift to Green Inhalers

The viability of combining clinical excellence with environmental responsibility is already evident in respiratory care. Standard metered-dose inhalers (MDIs) historically relied on hydrofluoroalkane propellants, which are potent greenhouse gases.

Sarah Ouanhnon, Head of Net Zero Delivery and Partnerships at NHS England, detailed ongoing collaborations between regulators, clinicians, and industry to accelerate the adoption of dry powder inhalers (DPIs). DPIs do not rely on chemical propellants and carry a fraction of the carbon footprint. Demonstrating the efficacy of this approach, Oxford University Hospitals reported an 18% reduction in total respiratory treatment emissions after safely transitioning eligible patients to green inhalers.

The Regulatory Dilemma: Safety vs. Sustainability

Historically, medicine regulatory bodies—such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA)—have operated under strict mandates focused exclusively on drug quality, safety, and efficacy. Environmental sustainability has rarely been part of their legal scope.

However, the WHO forum highlighted that existing regulatory frameworks can be adapted flexibly. For instance, minor modifications to post-approval manufacturing processes currently require extensive, multi-year validation testing. While these protocols are crucial for patient protection, they frequently delay the adoption of newer, more energy-efficient factory equipment or cleaner sterilization techniques.

Resource limitations further complicate this transition. In a Pharmapack industry survey, a majority of sector respondents cited key roadblocks to achieving green initiatives:

• 76% identified resource and capital constraints.

• 73% cited a lack of standardized data-sharing formats across borders.

• 70% noted insufficient regulatory guidance regarding green modifications.

• 43% expressed difficulty understanding the shifting regulatory scope.

Furthermore, specialized processes like cold-chain logistics—which require continuous, energy-heavy refrigeration to maintain vaccine and biologic stability—and high-temperature steam sterilization remain exceptionally difficult to decarbonize using current commercial technologies.

Looking Ahead: A Global Framework

The insights gleaned from this international consultation will serve as the foundation for the WHO’s upcoming White Paper, titled The Greener Pharmaceuticals’ Regulatory Highway. The paper aims to establish unified, international standards for measuring pharmaceutical emissions, preventing regulatory fragmentation that could place a double reporting burden on manufacturers.

The next pivotal milestone is scheduled for the Global Regulators Summit on June 19, 2026, where regulatory leaders will gather to finalize actionable implementation pathways. The formal publication of the completed White Paper is anticipated in July 2026.

“Working together will be essential,” concluded Dr. Gaspar. “This is not about choosing between sustainability and access. It is about identifying regulatory approaches that can help deliver both.”

For the general consumer, this initiative signals an upcoming shift where everyday medications will gradually become more environmentally sustainable without any loss in clinical quality, ensuring that the medicines prescribed to heal individual patients no longer inadvertently contribute to the global climate crisis.

Medical Disclaimer

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

https://www.who.int/news/item/12-06-2026-who-consultation-builds-momentum-for-coordinated-action-on-pharmaceutical-decarbonization